Cancer News and Research

Latest Cancer News and Research

Study opens new avenues of research to improve care for patients with COPD

Researchers from Boston University School of Medicine have pinpointed a genetic signature for chronic obstructive pulmonary disease from airway cells harvested utilizing a minimally invasive procedure.

12 Apr 2013

Researchers determine 3D structure of two proteins for first time

A team led by David Reverter, a researcher at the Institute of Biotechnology and Biomedicine of the UAB, has determined for the first time the three-dimensional structure of a protein pair: LC8 and Nek9.

12 Apr 2013

Gabriel Hortobagyi recognized with AACR-MICR Jane Cooke Wright Lectureship

Gabriel Hortobagyi, M.D., professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, will receive the Jane Cooke Wright Lectureship from the American Association for Cancer Research and its Minorities in Cancer Research membership group.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

Alzheimer's Association lauds Obama Administration for dedicating additional $100M to fight Alzheimer's

The Alzheimer's Association commends the Obama Administration for dedicating an additional $100 million within the President's FY 2014 budget toward the fight against Alzheimer's and the implementation of the National Plan to Address Alzheimer's Disease.

12 Apr 2013

New tool to identify air travelers with infectious disease developed

Researchers have developed a simple new tool to help governments worldwide decide whether to screen airplane passengers leaving or arriving from areas of infectious disease outbreaks.

11 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Gold nano-bullets to defeat cancer

Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).

11 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Deep inside your brain, a legion of stem cells lies ready to turn into new brain and nerve cells whenever and wherever you need them most. While they wait, they keep themselves in a state of perpetual readiness - poised to become any type of nerve cell you might need as your cells age or get damaged.

11 Apr 2013

QOPI Certification Program certifies MD Anderson Cancer Center Orlando

MD Anderson Cancer Center Orlando, known for inspiring hope through extraordinary care in Central Florida has now received a prestigious national certification from the Quality Oncology Practice Initiative (QOPI) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO). The QOPI Certification Program (QCP) certifies oncology practices that meet the highest quality standards for cancer care.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Scientists at The Scripps Research Institute have shed light on one of the major toxic mechanisms of Alzheimer's disease. The discoveries could lead to a much better understanding of the Alzheimer's process and how to prevent it.

11 Apr 2013

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

CanCELL cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013